Corwin Dale Hooks
Corporate Officer/Principal chez APPLIED THERAPEUTICS, INC.
Fortune : 1 M $ au 30/06/2024
Profil
Corwin Dale Hooks is currently the Chief Commercial Officer at Applied Therapeutics, Inc. He previously worked as the Head-Sales & Marketing at Genentech, Inc. from 2004 to 2014.
From 2014 to 2018, he served as the Chief Commercial Officer & Senior Vice President at Clovis Oncology, Inc. He then worked as the Vice President-Global Commercial Operations at Reata Pharmaceuticals, Inc. from 2019 to 2023.
Mr. Hooks holds an undergraduate degree from Stephen F.
Austin State University and an MBA from The University of North Carolina at Charlotte.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/04/2024 | 300 000 ( 0,26% ) | 1 M $ | 30/06/2024 |
Postes actifs de Corwin Dale Hooks
| Sociétés | Poste | Début |
|---|---|---|
| APPLIED THERAPEUTICS, INC. | Corporate Officer/Principal | 12/04/2024 |
Anciens postes connus de Corwin Dale Hooks
| Sociétés | Poste | Fin |
|---|---|---|
| REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2023 |
| CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | 29/10/2018 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Sales & Marketing | 01/01/2014 |
Formation de Corwin Dale Hooks
| The University of North Carolina at Charlotte | Masters Business Admin |
| Stephen F. Austin State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APPLIED THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
